Brief: Mustang Bio Announces Interim Phase 1/2 Data For MB-106 In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma

Mustang Bio

07/12/2020 12:36

Dec 7 (Reuters) - Mustang Bio Inc  MBIO.O :
    * MUSTANG BIO ANNOUNCES INTERIM PHASE 1/2 DATA FOR MB-106 IN
PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
    * MUSTANG BIO INC - 89% OVERALL RESPONSE RATE AND 44%
COMPLETE
RESPONSE RATE IN PATIENTS TREATED WITH MODIFIED CELL
MANUFACTURING PROCESS
    * MUSTANG BIO INC -  DATA FOR MB-106 SHOW EXTREMELY
FAVORABLE
SAFETY PROFILE AND CLINICAL ACTIVITY
    * MUSTANG BIO INC - IN PATIENTS WITH FOLLICULAR LYMPHOMA,
ORR WAS
85% AND CR WAS 57%
    * MUSTANG BIO INC - PLANS TO FILE AN IND APPLICATION IN Q1
OF 2021
TO ENABLE INITIATION OF A MULTICENTER PHASE 2 TRIAL OF MB-106

Source text for Eikon:  ID:nGNX940fW2 
Further company coverage:  MBIO.O 

 ((Reuters.Briefs@thomsonreuters.com;))